diphenylpiperazines have also been elaborated. Herein we report the synthesis of potent multiple-acting compounds from this new class. However, when two optimized representatives (6 and 14) possessing the desired in vitro profile were tested neither reduced the motor activity of mCPP treated animals. Comparative albeit limited in vitro structure–activity relationship (SAR) analysis and detailed in vivo studies are discussed
由于我们旨在研究针对5-羟
色胺(5-HT)转运蛋白(
SERT)和5-HT 2C受体的双重作用化合物的探索性计划的结果,确定了一系列新颖的3-
氨基-1-苯基丙氧基取代的二苯基
脲。从该集合中,显示出最高的5-HT 2C受体亲和力的两种有前途的化合物(2和3)强烈抑制了5-HT 2C受体激动剂1-(3-
氯苯基)
哌嗪(mCPP)诱导小鼠运动力减退。为了进一步实现该目标,还详细说明了(2-
氨基乙基)(苄基)
氨磺酰基二苯基
脲和二苯基
哌嗪。在这里,我们报告了这一新类中强效多作用化合物的合成。但是,当测试具有所需体外特征的两个优化代表(6和14)时,它们均未降低mCPP处理动物的运动活性。讨论了有限的体外结构-活性关系(
SAR)分析和详细的体内研究,并提出了其复杂行为的解释。